We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The lung transplant consists of replacing one or two sick lungs with healthy lungs. In general, transplants are carried out when there is a disease that involves severe and progressive chronic respiratory failure. Lung transplants started in 1981 in California. In Catalonia, this type of intervention is carried out exclusively at Vall d'Hebron University Hospital, for both children and adults.
Currently, 4,000 lung transplants are carried out every year around the world, including children and adults, especially in Europe, the United States, Canada and Australia. In the case of Catalonia, nine lung transplants are carried out per million inhabitants, a figure that puts us at the top of the tables. Our experience ranges from month-old babies to 70-year-olds.
Normally, it is a pneumologist with a patient with chronic respiratory insufficiency who contacts the Lung Transplant Unit for both adults and children at the Vall d'Hebron Hospital. From that first point of contact, the patient will be assessed by a multidisciplinary team in order to offer the best option, which might involve a transplant or simply medical treatment. It is important to remember that people who undergo lung transplants need to be strong enough to both wait for the operation and recover from it. This is a fundamental, complex requirement that must be met if the transplant is to provide benefits for the patient.
The survival rates for lung transplants are very positive. More than half of all patients are still alive after five years of the operation, and one in three patients after ten years. However, the goal of specialists is to continue researching to improve these results and prevent chronic rejection, and all the factors that lead to this complication.
Patients undergoing lung transplants must take an immunosuppressive therapy and prophylactics for an extended period of time. Most of these treatments are oral and in some cases may be inhaled.
In order to prevent complications, the medical advice given by your doctor should be followed precisely, avoid stress or over-exertion and make sure you follow the medication plan exactly. Aside from that, you can expect to lead a normal life.
The Anatomy Department studies diseases through direct microscope observation of tissues (biopsies, surgical samples, clinical autopsies) and body fluids (cytologies, fine needle aspiration punctures), to obtain the most accurate diagnoses to ensure proper treatment of the illness. Our mission is to offer the patient all the benefits of the best in medical, prognostic and predictive diagnosis using the most advanced molecular technologies.
Surgical pathology and cytopathology are a key part of diagnosing patients receiving treatment at our hospital. Our pathologists are highly specialised in a diverse range of pathologies, are internationally recognised and are leaders in the different fields of anatomopathological diagnosis. Our professionals can be found on commissions, committees and clinical management teams throughout the Hospital.
The Pathological Anatomy Teaching Unit is made up of pathological anatomy professionals from the Internal Medicine Department at the General Hospital. The Unit's healthcare activity is divided by specialisation with a total of 20 pathologists working in parallel with the clinical team. A modernized and young department dedicated to specialised training, with translational research by specialisation and a teaching role in the medicine and biomedicine degrees.
Pathological anatomy training itinerary
The Unit's activities include tissue processing techniques using microscopic and macro photography, the most common types of autopsy and biopsy, and foetal and infant paediatric autopsy in particular. The Gynaecology Unit also carries out cytology tests and attends intraoperative biopsies in rotation.
The Transplant Pathology Unit carries out protocol and monitoring biopsies, designed to be a procedure for fast diagnosis and treatment in cases of transplant rejection.
Duty shifts are carried out in surgical pathology at the hospital, in addition to processing surgical pieces and samples for the Foetal Tissue Bank, and carrying out autopsies during duty shifts.
It is a chronic inflammatory disease of the oesophagus caused and prolonged due to an allergic reaction. It is typified by difficulty swallowing (dysphagia) any food blockages in the oesophagus (food impaction) and rupturing of the oesophageal wall (oesophageal perforation).
The most common symptoms are:
If the inflammation of the oesophagus and related symptoms are left untreated, they will continue from childhood to adulthood. This inflammation causes structural changes to the oesophagus by remodelling the tissue. This can lead to fibrosis and oesophageal stricture. This means functional deterioration that significantly affects the patient’s quality of life.
From the first recorded case in 1993, eosinophilic oesophagitis has been found to affect 45 out of every 100,000 people, and has an incidence rate of 3.7 cases for every 100,000 people a year. This makes it the most common cause of dysphagia, spontaneous oesophageal perforation and food impaction in young patients.
For appropriate diagnosis, a gastroscopy must be carried out to take multiple biopsies from the oesophagus, since inflammatory alterations can be distributed unevenly. This technique also allows the response to treatment to be assessed.
Endoscopic analysis of the oesophageal mucous membranes is not sufficient to reach a firm diagnosis, as 10-15% of patients will have normal results of a endoscopy.
Treatment for EoE is based on three alternative therapies:
Early diagnosis is important to prevent complications arising from EoE. Early treatment and clinical and endoscopic monitoring is also essential.
Human papillomavirus (HPV) is generally spread through sexual intercourse and mainly infects the skin (penis, vulva, anus) or mucous membranes (vagina, cervix and rectum) of the genitals in both men and women. Likewise, it can also appear in the mouth and the pharynx and tonsils.
This is a frequently transmitted disease and in most cases it does not result in any pathology. It can, however, release a benign disease in the form of warts, or less commonly, different types of cancer. In women, HPV can cause cervical cancer.
HPV is spread via direct skin to skin contact during sex, and not through fluids. In around 90% of cases it disappears spontaneously, but it can be transmitted whilst the virus is present.
HPV is classified in terms of whether or not there is a risk of cancer developing:
It should be said that it is possible to be infected with more than one type of HPV. In addition, persistent infection can result in developing cancer of the cervix, vulva, penis, anus or oropharynx.
Specifically, the virus initiates dysplastic changes in the epithelial cells which continue to evolve until they produce an invasive cancer. This is a progressive process and the time from infection until developing the disease can be up to twenty years.
Genital warts or small protuberances or groups of different sizes and shapes may appear in the area of the genitals.
In the case of cancer, there are no symptoms until it is very advanced. In the case of cervical cancer, symptoms show up as:
In Catalonia, cancer of the womb occurs in 7.2 out of every 100,000 women per year (2003-2007). This represents 2.8% of all female cancers. Between the ages of 35-64 this figure rises to 16.1 cases for every 100,000 women. Furthermore, the risk of developing this disease for women who live to 75 is one in 106.
Anal cancer has an annual incidence rate of 1.8 cases for every 100,000 people, but in the case of men engaging in same-sex relations and infected with HIV, this rises to 70 or 128 cases for every 100,000.
When there is evidence of warts, diagnosis is usually clinical or by biopsy. Cancer is detected by cytology tests, which allow anomalous changes in the cells to be seen before they develop. If the test comes back anomalous it can be complemented by a colposcopy that allows magnified examination of the cervix and samples to be taken.
HPV detection is the main component of a preventative strategy to detect the virus before it reaches the point of disease.
There is no specific antiviral treatment for HPV.
In the case of warts, in most cases they can be eliminated through surgery, ointments or other treatments.
If cancer does develop, treatment will depend on the stage at which it is diagnosed. For example, if it is detected early in the cervix this can involve removing the damaged tissue, whilst in more advanced stages it may require a hysterectomy, radiotherapy or chemotherapy.
The use of condoms is essential to prevent HPV. There is also highly effective vaccine used as a way to prevent cervical cancer. Regular cervical smear tests (Papanicolau test) are also carried out as a form of screening. This strategy, however, is changing due to the techniques used to detect the virus which, together with the smear test, are enabling the different stages of the disease to be monitored (acquisition, persistence, progression to precancerous lesions and invasion).
Pathological anatomy, Cross-departmental services
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.